✔ COMPLIANT
★★☆
Biotechnology & Medical Research | USA
Business: PASS
0 has cleared the Business screen. Its business activity is compliant with the Shariah standard. If you find this result mistaken or questionable, let us know in the comments.
Financials: PASS
The financials pass two standards and fail in one.
FTSE
| Debt/A | 2.47% | ✔ |
| Cash/A | 91.57% | ✘ |
| (AR+C)/A | 91.57% | ✘ |
AAOIFI
| Debt/MC | 0.7% | ✔ |
| Cash/MC | 0% | ✔ |
DJIM
| Debt/24MC | 0.39% | ✔ |
| Cash/24MC | 91.57% | ✔ |
| AR/24MC | % |
Total Analysts: 4
Analysts Price Targets
1
2
3
4
5
Recommendation Rating
Low: 4
High: 22
| Market cap | 135989851 |
| Assets | 38282000 |
| Dividends per Share | |
| Revenue Growth % | 0 |
Candel Therapeutics, Inc, formerly Advantagene, Inc, is a clinical stage biopharmaceutical company. The Company is focused on helping patients fight cancer with oncolytic viral immunotherapies. Its engineered viruses are designed to induce immunogenic death through viral-mediated cytotoxicity in cancer cells, therefore releasing tumor neo-antigens and creating a pro-inflammatory microenvironment at the site of injection. Its approach combines a knowledge of viral immunotherapy with clinical experience across a range of indications. Its product candidate, CAN-2409 program, is in Phase III clinical trial. Its lead HSV product candidate, CAN-3110, is in Phase I clinical trial. The Company also designs candidates based on its HSV platform for the treatment of solid tumors. The Company’s oncolytic viral immunotherapy platforms is based on genetically modified adenovirus and herpes simplex virus (HSV) constructs. Its preclinical models and clinical trials use its approach.
| ✘ FTSE | ✔ AAOIFI | ✔ DJIM |
✔ COMPLIANT
We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan.
Responses